BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 276 filers reported holding BIO-TECHNE CORP in Q2 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $321,358 | +27.5% | 4,721 | +548.5% | 0.01% | 0.0% |
| Q2 2022 | $252,000 | -49.2% | 728 | -36.5% | 0.01% | -37.5% |
| Q1 2022 | $496,000 | -77.1% | 1,146 | -72.6% | 0.01% | -78.9% |
| Q4 2021 | $2,162,000 | +1.6% | 4,179 | -4.9% | 0.04% | -11.6% |
| Q3 2021 | $2,129,000 | +21.4% | 4,393 | +12.8% | 0.04% | +22.9% |
| Q2 2021 | $1,753,000 | +43.1% | 3,893 | +21.3% | 0.04% | +29.6% |
| Q1 2021 | $1,225,000 | +242.2% | 3,209 | +184.2% | 0.03% | +170.0% |
| Q4 2020 | $358,000 | +92.5% | 1,129 | +50.5% | 0.01% | +66.7% |
| Q3 2020 | $186,000 | +67.6% | 750 | +78.1% | 0.01% | +100.0% |
| Q2 2020 | $111,000 | +753.8% | 421 | +501.4% | 0.00% | – |
| Q1 2020 | $13,000 | -93.6% | 70 | -93.3% | 0.00% | -100.0% |
| Q3 2019 | $204,000 | -60.1% | 1,045 | -57.5% | 0.01% | -58.3% |
| Q2 2019 | $511,000 | -30.8% | 2,456 | -34.2% | 0.01% | -33.3% |
| Q1 2019 | $738,000 | +37.2% | 3,731 | +0.5% | 0.02% | +28.6% |
| Q4 2018 | $538,000 | -8.5% | 3,714 | +28.2% | 0.01% | +16.7% |
| Q3 2018 | $588,000 | +539.1% | 2,896 | +362.6% | 0.01% | +500.0% |
| Q2 2018 | $92,000 | -16.4% | 626 | -33.4% | 0.00% | -33.3% |
| Q2 2017 | $110,000 | -0.9% | 940 | -13.9% | 0.00% | 0.0% |
| Q1 2017 | $111,000 | -0.9% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $112,000 | +0.9% | 1,092 | +7.7% | 0.00% | 0.0% |
| Q3 2016 | $111,000 | – | 1,014 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |